European Journal of Biomedical and Pharmaceutical Sciences

OCULAR DRUG DELIVERY SYSTEM: A REVIEW ON ITS RECENT ADVANCEMENT

Swapnil Lembhe* and Asish Dev.

ABSTRACT

Ophthalmic drug delivery is one of the most interesting and challenging problem facing the pharmaceutical companies in the market. Low bioavailability of the drug is the main problem. Controlled drug delivery systems has many advantages over conventional dosage forms like improved drug bioavailability, reduced toxicity and decreased dosage frequency.[8] In-situ-forming ophthalmic drug delivery systems can overcome the problems like Poor bioavailability of ophthalmic solutions caused by dilution and drainage from the eye. Different types of dosage forms such as nanoparticles, liposomes and microemulsions have been developed to improve the bioavailability of the drugs. Drug delivery can be affected by the Static barriers (different layers of cornea, sclera, and retina including blood aqueous and blood–retinal barriers), dynamic barriers (choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution), and efflux pumps in conjunction. Newer research in ophthalmic drug delivery systems is carried out not only to extend the contact time of the vehicle at the ocular surface, but which at the same time slow down the removal of the drug. Identification of influx transporters on various ocular tissues and designing a transporter-targeted delivery of a parent drug has gathered momentum in recent years. This review focuses on recent development in conventional and non-conventional ophthalmic dosage formulation and products used for prolonged contact time of drugs with the cornea and increases their bioavailability.

Keywords: Eye, Ocusert, Minidisk, liposomes, nanoparticles, eye drops.